Minerva's proprietary primitive stem cell growth factor
dramatically increases the efficiency of making human iPS cells, which greatly reduces the time and the cost of making iPS cells for research or for personalized stem cell banking.
According to background information in the research article, GCSF is a blood stem cell growth factor
or hormone routinely administered to cancer patients whose blood stem cells and white blood cells have been depleted following chemotherapy or radiation.
To characterize DTC, we focused on fibroblast growth factor 2 (FGF2), a known stem cell growth factor
also relevant for the in vitro growth of micrometastatic cells (3).